ArticleJournal of biochemical and molecular toxicology2026
PERK Signaling Pathway Mediates the Hepatoprotective Effects of Naringenin Against Cadmium-Induced Liver Injury in Rats.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cadmium (Cd), a heavy metal element with extensive industrial applications, exhibits significant toxicological risks in biological systems (Zhu et al. 2019). Naringenin (Nar), a bioactive flavonoid possessing potent antioxidant properties, demonstrates ameliorative effects against Cd toxicity. 24 male SD rats were randomly allocated into four groups: Control group; Cd group; Cd + Nar group; Nar group. Determination of biochemical indicators, antioxidant indicators; reverse transcription quantitative real-time PCR (RT-qPCR) and Western blot were used to detect the expression levels of related mRNA and protein. Cd exposure reduced rat body weight and increased liver-to-body weight ratio, along with elevations in ALT, AST, GSH, and MDA. Conversely, Cd + Nar treatment increased body weight, reduced liver organ coefficient, and decreased these biomarkers. HE staining revealed expanded hepatic sinusoids in the Cd group. RT-qPCR and Western blot showed Cd upregulated GRP78, PERK, and CHOP expression at both mRNA and protein levels, while Cd + Nar treatment attenuated these increases. Cd activates the PERK signaling pathway through ERS and causes liver damage. Nar can reduce liver toxicity. The mechanism may be related to the inhibition of PERK activation by Nar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.